Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Novo Nordisk has officially launched Ozempic in India, marking a significant expansion of its presence in one of the world’s fastest-growing markets for diabetes and obesity treatments. The launch ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success ...

Novo Nordisk A/S advances metabolic and rare disease treatments through global research, manufacturing, and clinical ...

Once a celebrated leader in the pharmaceutical sector, Novo Nordisk is now engaged in a fierce battle for investor confidence ...

Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter, but management reduced 2025 guidance to 8%-14% sales growth and 10%-16% operating ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

News comes after layoffs announced on Wednesday Other companies, US administration have scrapped home working Novo employees can still make individual arrangements COPENHAGEN, Sept 11 (Reuters) - ...